LYEL News and Press, Lyell Immunopharma Inc. From 02/26/25

XPEL Inc. (XPEL) is expected to report $0.41 for Q4 2024 MGP Ingredients Inc. (MGPI) is expected to report $1.49 for Q4 2024 Kratos Defense & Security Solutions Inc. (KTOS) is expected to report $0.05 for Q4 2024 Albany International Corporation (AIN) is expected to report $0.65 f...

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced today that members of its senior management team will present and...

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3 rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2 nd line by early 2026 Presenting additional data from the ongoing Phase 1-2 trial in 3 rd line+ setting and i...